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Purpose: The purpose of this study was to investigate the serum hypercoagulability state and 
common viral and protozoan infections in Coats’ disease versus a normal control group.
Materials and methods: In this comparative case series, 22 consecutive patients with Coats’ 
disease and 19 non-Coats’ patients undergoing lensectomy for congenital, traumatic, or senile 
cataract between January 2011 and June 2014 were included. Laboratory data for hypercoagu-
lability states and common viral and protozoan infections were investigated.
Results: The mean age for the Coats’ group was 14.5 years (median 8 years, range: 2 months 
to 59 years), and for the control group it was 30.6 years (median 17 years, range: 2–82 years). 
In patients aged 10 years or younger, anticytomegalovirus immunoglobulin G (IgG) (P#0.01), 
homocysteine (P=0.03), and serum beta globulin (P,0.001) were associated with Coats’ dis-
ease. In those older than 10 years, higher serum protein S (P=0.04), beta globulin (P=0.05), 
and gamma globulin (P=0.04) were related to Coats’ diagnosis. After adjusting for sex and age 
as confounding factors, only beta globulin was found to be associated with Coats’ disease in 
logistic regression analysis (odds ratio: 1.8, 95% confidence interval: 1.0–3.1, P=0.02).
Conclusion: Serum beta globulin levels appear to be elevated in patients with Coats’ disease.
Keywords: anti-cytomegalovirus antibody, anti-herpes simplex antibody, Coats’ disease, blood 
hypercoagulability state, retinal telangiectasia, serum electrophoresis
Introduction
Coats’ disease first described in 1908,1 is an idiopathic, typically unilateral, reti-
nal vasculopathy that manifests with retinal telangiectasia, exudation, and retinal 
detachment.2–4 Coats’ disease shows a male predominance, occurs more often in 
early childhood, and can lead to vision loss. Less commonly, this condition presents 
in teenagers and young adults often with less aggressive features.4 Coats’ disease is a 
major simulator of retinoblastoma, a life-threatening pediatric ocular malignancy.1–4
In a study of angiographic findings of patients with Coats’ disease, we noticed 
that occlusion of the retinal microvasculature with peripheral nonperfusion and shunt 
or microshunt formation between arterioles and venules in the retina was a promi-
nent finding.5 This led to a speculation regarding serum factors that could lead to the 
microocclusions, such as a hypercoagulability state. Realizing that such a state would 
more likely lead to bilateral manifestations, we continued to explore serum features in 
Coats’ disease. In 2012, we found a significantly high level of anti-cytomegalovirus 
(CMV) immunoglobulin G (IgG) in 92% of Coats’ patients, higher serum proteins C 
and S, anti-herpes simplex virus (HSV) IgG I/II, alpha-2 globulin, and homo-
cysteinemia in patients with Coats’ disease.6 In the second step of the analysis, it was 
planned to compare these factors in patients with Coats’ disease with a control group. 
Herein, we evaluated serum hypercoagulable factors and viral and protozoan diseases 
in patients with Coats’ disease versus normal controls.
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Materials and methods
A prospective, single-center, comparative, consecutive cross-
sectional study was conducted for evaluating blood hypercoag-
ulability state and infectious diseases, including CMV, herpes 
simplex, Epstein-Barr virus (EBV), toxoplasma and toxocara 
infections, in all patients with Coats’ disease from February 
2011 to December 2013. The research adhered to the tenets 
of the Declaration of Helsinki and the study was approved by 
Tehran University of Medical Sciences Institutional Review 
Board. Each patient or parents were carefully informed about 
the purpose of the research, and oral consent for laboratory 
examinations was obtained. Each patient or parents provided 
their written informed consent for this study.
Coats’ disease was defined as unilateral or bilateral retinal 
vasculopathy characterized by retinal telangiectasia, capillary 
non-perfusion, multiple aneurysmal formation, exudation, 
and exudative retinal detachment.1–9 Patients with Coats’ 
disease were grouped into those aged 10 years or less versus 
those older than 10 years. Clinical factors were compared 
to a control group, which consisted of patients with cataract 
undergoing lensectomy for congenital, traumatic, or senile 
cataract, with no evidence of retinal vascular disease.
Patients were evaluated with best-corrected visual acuity, 
indirect ophthalmoscopy for fundus features and color fundus 
photography, fluorescein angiography, and B-scan echog-
raphy as needed. Fluorescein angiography was performed 
using a scanning laser ophthalmoscope (HRA, Heidelberg, 
Germany) or RetCam 120 (Clarity Medical Systems, Inc., 
Pleasanton, CA, USA).
The blood sample for serum studies was obtained from 
patients immediately before the treatment of Coats’ disease. 
Treatment options included cryotherapy, photocoagulation, 
and intravitreal antivascular endothelial growth factor and/or 
subtenon triamcinolone depending on the patient’s condition. 
Serum studies included hemoglobinopathies by hemoglobin 
electrophoresis; serum protein electrophoresis; coagulable 
states by serum protein C, protein S level, antiphospho-
lipid antibody, anticardiolipine antibody, antithrombin III, 
homocysteine level, and lipid profile; and infectious states 
by anti-HSV IgG, anti-CMV IgG, anti-EPV, anti-toxoplasma 
and anti-toxocara serum antibodies were measured with a 
enzyme-linked immunosorbent assay (ELISA) technique 
according to the manufacturer’s protocol.
statistical analysis
Statistical analyses were performed using Statistical Package 
for Social Sciences (v 17.0; SPSS, Chicago, IL, USA). All 
data are presented as mean ± standard deviation (SD) or 
median (range of data). A Mann–Whitney test was used for 
quantitative or skewed distributed parameters. To assess 
the relationship between the qualitative variable and Coats’ 
diagnosis, Fisher’s exact test was applied. Logistic regression 
models were used to assess the relation of target exposure 
with Coats’ diseases adjusting for possible confounding 
factors. A P-value of less than 0.05 was considered to be 
statistically significant.
Results
During the study period, there were 22 patients with Coats’ 
disease (Figure 1) and 19 control patients. Of those with 
Coats’ disease, 13 were 10 years or younger and 9 were older. 
(Table 1). The mean age for Coats’ patients was 14.5 years 
(median 8 years, range: 2 month to 59 years), and for the 
control group it was 30 years (median 17 years, range: 
2–82 years) (Table 2).
For those 22 patients with Coats’ disease, the mean time 
from the first notice of the disease by patients (or parents) 
to diagnosis was 7.1±5.4 months in the younger age group 
(#10 years old) and 7.8±9.9 months in the older age group 
(.10 years old). There were three (13.6%) with bilateral 
involvement. Using the Coats’ disease classification,4 the condi-
tions of the eyes were classified as stage 1 (n=0), stage 2 (n=7), 
stage 3 (n=12), stage 4 (n=3), and stage 5 (n=0). Total retinal 
detachment was seen in six (28%) cases, whereas macular 
detachment was seen only in three (14%) cases. In two (9%) 
cases, there was no retinal detachment. The temporal and infe-
rior regions were the most common sites for retinal detachment. 
Using fluorescein angiography, avascular non-perfused areas 
were found in 18 (82%) cases, located in the periphery region 
in 10 (46%) and in the macular region in 2 (9%) (Table 1).
The first step of analysis was a comparison of the two 
age groups of Coats’ disease (#10 years vs .10 years). This 
revealed no significant difference in the lipid profile, serum 
antithrombin III, anticardiolipine and antiphospholipid anti-
body serum antibody titer as well as polymerase chain reaction 
test for toxoplasma, toxocara, or EBV in the two groups. 
There was statistical difference (Mann–Whitney test-skewed 
deviation) in the two groups with regard to hemoglobin 
(P=0.02), serum anti-HSV IgG (P=0.05), anti-CMV IgG 
(P=0.05), protein C (P=0.07), homocysteine (P,0.01), 
serum alpha-2 globulin (P,0.01), and serum gamma globulin 
(P=0.05). Due to the small sample size in each age group, the 
logistic regression analysis was inconclusive.
The second step of analysis involved comparison of labo-
ratory findings in Coats’ disease versus the normal control 
group (Table 2). The serum levels in both Coats’ and control 
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patients were compared using the Mann–Whitney test. There 
was no significant difference in the lipid profile, serum anti-
thrombin III, anticardiolipine, and antiphospholipid antibody 
serum antibody titer as well as polymerase chain reaction 
for toxoplasma, toxocara, or EBV. However, in the control 
group, the serum titer of anti-HSV IgG was higher and that 
of anti-CMV IgG was lower. In Coats’ group, serum beta 
globulin was significantly higher in both young (#10 years, 
P,0.001) and old (.10 years, P=0.05) subgroups compared 
to controls. Applying Bonferroni correction did not change 
the results of serum beta globulin in the group less than 10 
years old.
Logistic regression analysis for the main serologic find-
ings in Coats’ patients (irrespective of age) and control group 
was performed. After adjustment for age and sex, a signifi-
cant association persisted for the presence of higher titer of 
serum beta globulin in Coats’ disease compared to controls 
(odds ratio [OR]: 1.8, 95% confidence interval [CI]: 1.0–3.1, 
P=0.02) (Table 3). Anti-HSV showed a mild negative impact 
(P=0.01, OR =−0.94) on the diagnosis of Coats’ disease. 
After adjusting for age and sex, in those less than 10 years, 
the serum beta globulin was found to be significantly asso-
ciated with the diagnosis of Coats’ disease (OR: 6.3, 95% 
CI: 1.2–32.6, P=0.02). In patients greater than 10 years with 
Coats’ disease, there was a non-significant association with 
the diagnosis of Coats’ disease (OR: 1.3, 95% CI: 0.8–2.0, 
P=0.24). For the older age, anti-HSV antibody was borderline 
significant (OR: 0.98, 95% CI: 0.97–1.00, P=0.05). The small 
sample size precluded more conclusive results in the logistic 
regression analysis, adjusting for all other covariates.
Discussion
In this study, we could not find any association between 
hypercoagulability state and Coats’ disease (compared to 
controls). The only factor associated with Coats’ disease 
was elevated serum beta globulin mainly in the younger age 
group. We also recognized the negative impact of anti-HSV 
antibody on Coats’ disease in the older age group.
Serum beta globulins are grossly measured by electro-
phoresis. Serum protein electrophoresis is a technique to 
assess the two major fractions of protein in blood, including 
albumin and globulins.10 Albumin is a transport protein that 
Figure 1 Clinical appearance of a patient with Coats’ disease. (A and B) The fundus image of a patient with Coats’ disease with exudative total retinal detachment. There 
is central arteriolar mild dilation and tortuosity. Peripheral telangiectatic vessels along aneurysmal changes are visible. Many microvascular shunts nearly in 360° of periphery 
and midperiphery of retina are evident. (C and D) Angiographic finding as telangiectatic vessels, microaneurysms, sacular aneurysms, shunt vessels and peripheral avascular 
area in temporal and inferior retina.
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Table 1 Coats’ disease based on the age category: demographic features
Features Age #10 years
(13 cases) N (%)
Age .10 years
(9 cases) N (%)
Fisher’s exact test
P-value
sex
Male 8 (61.5) 6 (66.7) 1.00
Female 5 (38.5) 3 (33.3)
eye affected
right 8 (61.5) 5 (55.6) 0.23
left 5 (38.5) 4 (44.4)
laterality
Unilateral 10 (76.9) 9 (100) 0.23
Bilateral 3 (23.1) 0 (0)
Telangiectatic vessels 10 (76.9) 4 (44.4) 0.51
aneurysms 9 (69.2) 4 (44.4) 0.37
exudation 9 (69.2) 9 (100) 0.13
Subretinal fluid 10 (76.9) 5 (55.6) 0.52
Tractional retinal detachment 6 (46.2) 3 (33.3) 0.50
Subretinal fibrosis 5 (38.5) 1 (11.1) 1.00
retinal traction 2 (15.4) 2 (22.2) 0.70
subretinal hemorrhage 3 (23.1) 1 (11.1) 1.00
Vitreous hemorrhage 0 (0) 0 (0) 1.00
Pre-retinal hemorrhage 3 (23.1) 0 (0) 0.53
Vasoproliferative tumor 2 (15.4) 2 (22.2) 0.52
retinal cyst 5 (38.5) 2 (22.2) 1.00
Pigmentary changes 6 (46.2) 2 (22.2) 0.48
Cystic changes in vitreous 0 (0) 1 (11.1) 0.09
Fibroglial tissue 4 (30.7) 1 (11.1) 0.41
subretinal band 3 (23.1) 1 (11.1) 0.53
retinal fold 2 (15.4) 1 (11.1) 0.10
Vascular sheeting  
(arterioles and/or venules)
8 (61.5) 2 (22.2) 0.25
Vascular occlusion  
(large arterioles and/or venules)
3 (23.1) 0 (0) 0.49
Peripheral non-perfusion  
(more temporal)
6 (46.2) 1 (11.1) 0.68
shunt vessels 1 (7.6) 0 (0) 0.68
retinal tear 2 (15.4) 0 (0) 0.50
Table 2 Coats’ disease based on the age category: comparison of serum values with normal controls
Features Age #10 years median (range) Age .10 years median (range)
Coats’ disease 
group  
(13 cases)
Control 
group 
(9 cases)
Mann–Whitney 
(P-value)
Coats’ disease 
group 
(9 cases)
Control  
group 
(10 cases)
Mann–Whitney 
(P-value)
age (Mo) 48 (2–120) 48 (36–108) 0.48 276 (144–708) 708 (204–984) 0.07
WBC (×103/dl) 8.8 (5–61) 6.8 (5–101) 0.10 7.5 (5.5–9.5) 8.6 (5–11.3) 0.35
hb (g/dl) 13.3 (9.4–15) 12 (11–14) 0.36 15.3 (13.4–16.6) 15.4 (13.4–16.9) 0.90
PlT (103/dl) 372.5 (260–627) 354 (222–490) 0.61 281 (211–463) 242 (201–312) 0.31
serum anti-hsV igg ,20 (U/ml) 0.2 (0.1–52.8) 7.0 (3.4–160) 0.004 3.8 (0.1–201) 201 (3–201) 0.02
serum anti-CMV igg ,1 (U/ml) 197.0 (0.8–501) 69.6 (4.9–127) ,0.01 454 (124.8–501) 298 (76.3–501) 0.37
Protein C (70–130 unit%) 86 (54–99) 84 (50–105) 0.80 104 (52–138) 105.5 (95–131.5) 0.87
Protein s
(male: 77–143,  
female: 55–125 unit%)
82 (60–115) 63 (30–11) 0.11 86 (76–114) 76.5 (56–98) 0.04
homocysteine 7 (5.2–10) 5 (5–7.4) 0.03 11.8 (8.1–19.8) 19.6 (9.6–53) 0.30
serum albumin (g/dl) 41.5 (35.9–49.4) 46.1 (29.1–49.8) 0.05 41.4 (33–46.8) 42.7 (35.5–46.8) 0.36
serum α1 globulin (2–6 g/dl) 4 (2.1–6) 3.3 (2.9–3.9) 0.05 4.3 (3.2–6) 4 (2.2–5.1) 0.23
serum α2 globulin (8–13 g/dl) 16.6 (11.4–20.5) 16.3 (14.9–20.9) 0.88 12.6 (11.8–16.2) 15.5 (12–18.7) 0.006
serum β globulin (12–19 g/dl) 18.7 (15.7–21.8) 15.2 (13.5–17.1) ,0.001 18.2 (16.1–21.9) 16.2 (14.8–22.2) 0.05
serum γ globulin (15–25 g/dl) 20.8 (9.1–29.6) 20.7 (15.5–22.6) 0.52 22.8 (20.7–28) 20 (18–28.1) 0.04
Abbreviations: CMV, cytomegalovirus; hb, hemoglobin; hsV, herpes simplex virus; igg, immunoglobulin g; Mo, month; PlT, platelet; WBC, white blood cell count.
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plays a significant role in fat solubility.11 The globulin frac-
tion of blood includes hundreds of serum proteins, including 
carrier proteins, enzymes, complement, and immunoglobu-
lins. Globulins are divided into four groups by electropho-
resis: alpha, alpha-2, beta, and gamma, depending on their 
migratory pattern between the anode and the cathode of the 
electrophoresis test.11 The beta fraction of serum globulins 
is known to have two peaks, named as beta 1 and beta 2. 
Beta 1 is composed of mostly transferrin, and beta 2 contains 
beta-lipoprotein.12 IgA, IgM, and sometimes IgG, along with 
complement proteins (C3), beta-2 microglobulin, plasmino-
gen, angiostatins, properdin, sex hormone-binding globulin, 
transferrin, hemopexin, and factor H, can also be identified 
in the beta fraction.10–12 These proteins carry out numerous 
biological functions in the human body, including iron trans-
port and monitoring immune response.10,11
Beta globulin protein can be elevated or depressed in 
various diseases. Beta globulin is found to be elevated in 
iron deficiency anemia, hypercholesterolemia, pregnancy, 
estrogen therapy, and also substantially increased in liver 
disease.9,10,13,14 It is found to be decreased in malnutrition, cir-
rhosis, and immune deficiency due to decreased synthesis, and 
in nephrotic syndrome due to protein loss in the kidney.11
In this series of Coats’ disease, the beta globulin fraction 
was elevated, which is particularly evident in patients lesser 
than 10 years. This age-related difference could correlate with 
milder manifestations of Coats’ disease in older patients. The 
relationship of this fraction with Coats’ disease is unclear, but 
could correlate to higher C3 (complement protein 3) level or 
other factors. Complement 3 is an important protein in the 
immune system, which plays a vital role in the acute phase 
response. It controls several biological processes, including 
cell lysis, chemotaxis, anaphylaxis, vascular permeability, 
and cellular membrane adhesion. This protein is categorized 
as a beta globulin and might represent the elevation of beta 
globulin in Coats’ disease in this report.12,15–18
Chronic low-grade inflammation has been correlated 
with elevated C-reactive protein, as well as complement 
C3 plasma levels, and these can be predictive of arterial 
thrombotic events.16–20 Elevated C3 is also associated with 
prolonged fibrinolysis.18,21–23 Both of these roles could relate 
to the vascular pathology of Coats’ disease.
The discrepancy found in the younger and older age groups 
could suggest a difference in the main pathophysiological 
basis of Coats’ disease in children and adults. More studies 
are needed for the confirmation of this observation. There are 
limitations of this study, including the small sample size and 
unclear relevance of beta-globulin relationship to the condition 
studied. This relationship could be further explored with larger 
cohort and more precise fractionation of the beta-globulin 
subgroup to better understand the exact protein(s) that contrib-
ute to this finding and its relationship to Coats’ disease.
Conclusion
This analysis demonstrated that children with Coats’ 
disease showed elevated serum levels of beta globulin. We 
speculate that this finding could reflect the known fluorescein 
angiographic-evident ischemic component and possibly now 
a low-grade inflammatory component.
Disclosure
The authors report no conflicts of interest in this work.
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Abbreviations: CI, confidence interval; HSV, herpes simplex virus; CMV, 
cytomegalovirus; igg, immunoglobulin g; Or, odds ratio.
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